Hepatocellular carcinoma

HCC liver
Long-term survival in patients with massive hepatocellular carcinomas (MHCC) was improved when treatment consisted of transcatheter arterial chemoembolization (TACE) combined with percutaneous microwave coagulation therapy (PMCT) compared with TACE alone, according to a study publishes in Cancer… Read More
S Padia
Ablation and stereotactic body radiation therapy (SBRT) are both effective treatments for patients with hepatocellular carcinoma (HCC), especially those in early stages of the disease. Siddharth A. Padia, MD explains what interventional radiologists need to know when deciding between ablation and… Read More
HCC cells
The potential value of α-fetoprotein (AFP) classification in clinical practice is demonstrated according to a study published in the Journal of Vascular and Interventional Radiology. The results showed that AFP categories agreed moderately with modified Response Evaluation Criteria In Solid Tumors… Read More
HCC cells
In patients with ultrasound (US)-invisible early stage hepatocellular carcinoma (HCC), the combined therapy of conventional transarterial chemoembolization (cTACE) followed by fluoroscopy-guided radiofrequency ablation (RFA) was safe and effective resulting in less local tumor progression (LTP) and… Read More
HCC cells
For the treatment of patients with unresectable hepatocellular carcinoma (HCC), the combination of transcatheter arterial chemoembolization (TACE) with iodine [131I] metuximab infusion may improve local efficacy and overall survival when compared with TACE alone, according to an article in Clinics… Read More
HCC liver
A new study found that Y90 radioembolization with glass microspheres given at a boosted dose in patients with large hepatocellular carcinomas (HCCs) may show favorable tumor response. The results, which were published in the Journal of Vascular and Interventional Radiology, also found that the… Read More
HCC liver
Using 3D voxel-based dosimetry in patients with hepatocellular carcinoma (HCC) treated by yttrium-90 (90Y) resin microspheres radioembolization, a new study determined that complete  tumor targeting and 90Y dose to tumor are independent factors associated with clinical outcomes. The results were… Read More
HCC liver
Liver resection was found to have significant survival benefits over TACE in patients with Barcelona Clinic Liver Cancer (BCLC)-B hepatocellular carcinoma (HCC), according to a study published in Hepatology International. However, a significantly increased incidence of treatment-related mortality… Read More
software
A commercially available 3-dimensional (3D) workstation and liver analysis software can be useful for estimating the embolic area in conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC), according to a study published in the journal CardioVascular and… Read More
liver
Some patients with unresectable hepatocellular carcinoma (HCC) have prolonged survival after treatment with yttrium-90 radioembolization. Researchers conducted a study to analyze which factors can help predict “Super Survivor” outcomes, which were defined as surviving 3 or more years after Y-90… Read More